ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.

C A Gomez-Roca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.